Hyperthermic Intraperitoneal Chemotherapy to Gynaecological Oncology

Dear Colleagues,

The role of hyperthermic intraperitoneal chemotherapy (HIPEC) as a standard treatment procedure in the field of gynecologic oncology is controversial. Although widely discussed and studied as a subsidiary method of interval cytoreductive surgery, HIPEC remains debatable even in the management of advanced and recurrent epithelial ovarian cancer. Hence, many large trials support the safety and efficacy of the method regarding the extension of overall survival in well selected EOC patients. Interestingly, encouraging findings support the effectiveness of HIPEC even performed at the time of primary debulking surgery in stage III EOC patients, by whom a complete cytoreduction is anticipated, and large ongoing trials’ results will be shortly available. The promising results of studies investigating HIPEC combined with adjuvant chemotherapy with platinum compounds in the management of advanced stage peritoneal disseminated endometrial and cervical cancer add to recent evidence and verify further more thorough research. Remarkably, peritoneal carcinomatosis from non-gynecological origin in patients with abdominally confined disease has been considered an indication for hyperthermic intraperitoneal chemotherapy. Originally in cases of pseudomyxoma peritonei and malignant peritoneal mesothelioma followed by gastric, colorectal and even breast cancer patients with pelvic peritoneal metastases, many authors have published supporting data about explorative surgery followed by cytoreduction and HIPEC.

Nevertheless, more prospective multi-center randomized studies need to be designed in order to draw safe conclusions and determine which patients could benefit from the implementation of this approach. Further issues to be determined encompass robust data of the surgical procedures, the art and dose of chemotherapeutic regimens as well as the temperature and duration of the hyperthermic arm that will warrant the optimal oncological outcome and support the recommendation of HIPEC by the gynecological cancer community.

The aim of our special issue is to publish interesting studies in the field exploring the indications, technique, future challenges. We welcome authors to submit case reports, case series, retrospective studies, randomized trials and reviews regarding the role of HIPEC in different gynecological cancers.

Prof. Dr. Christos Iavazzo, Dr. Alexandros Fotiou, Alexandros Fotiou, and Dr. Anastasia Prodromidou

Guest Editors

Manuscripts should be submitted via our online editorial system at https://www.ejgo.net by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.